
Academic Journal
Q3Lung Cancer Management
About Lung Cancer Management
Lung Cancer Management is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q3, with an SJR of 0.468 and H-index of 9.
Coverage: 2012-2014, 2020-2026. Research categories: Oncology (Q3); Pulmonary and Respiratory Medicine (Q3).
Source-backed journal facts
Topics in published research
Lung Cancer Treatments and Mutations; Lung Cancer Diagnosis and Treatment; Lung Cancer Research Studies; Cancer Genomics and Diagnostics; Cancer Immunotherapy and Biomarkers; Occupational and environmental lung diseases.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-01. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study
Lily Yang, Sana Iman Mutalib, Elizabeth Qi, Andrew Zeng et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2738583Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre
Kohei Fujita, Takuma Imakita, Naoki Fujimoto, Saiki Yoshimura et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2707910Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK
Hannah Le, Daniel Ladino, Chrissy Lowry, Nada Rifi et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2696220Correction
2026-12-31 · DOI: 10.1080/17581966.2026.2654211Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective
Ryu Kanzaki, Jiro Okami
2026-12-31 · DOI: 10.1080/17581966.2026.2654371Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer
Mengmeng Liu, Lu Zhong, Tong Liu
2026-12-31 · DOI: 10.1080/17581966.2026.2654888Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life
Jeremy P. Harris, Christina Boyd, Mengying Shi, Michael Reilly et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2635332CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology
Tingting Wang, Jingjing Fan, Xiaoyan Lv, Cong Zhang et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2625649Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China
Bingqi Hu, Jing Xue, Dingsiman Li, Jia Duan et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2622902Leveraging machine learning to predict de novo skin malignancy following lung transplantation
Nasim Nosoudi, Amir Zadeh, Rayna Nichols, Cameron Kiani et al.
2026-12-31 · DOI: 10.1080/17581966.2026.2617115Construction and validation of an oxidative phosphorylation-related gene signature in lung squamous cell carcinoma patients
Ninghuang Dai, Chen Fang, Yu Gu, Bin Wang et al.
2025-12-31 · DOI: 10.1080/17581966.2025.2597179Negative social determinants of health are linked to lung cancer screening underutilization
Vuong V. Do, Eduardo R. Núñez, Fatima G. Wilder, Nhung Nguyen et al.
2025-12-31 · DOI: 10.1080/17581966.2025.2583639Lung cancer screening in limited resource regions: the 3rd Brazilian Early Lung Cancer Trial (BRELT3/mobile ProPulmão)
Ricardo Sales dos Santos, Ricardo G. Figueiredo, Juliana P. Franceschini, Cesar Augusto de Araújo Neto et al.
2025-12-31 · DOI: 10.1080/17581966.2025.2513179The association between blood-based HYAL2 methylation and early-stage lung cancer: a case-control study
Rong Qiao, Xiajie Zhou, Wenli Li, Runbo Zhong et al.
2025-12-31 · DOI: 10.1080/17581966.2025.2477411Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC
Christos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, Romain Raymond et al.
2025-12-31 · DOI: 10.1080/17581966.2025.2477418Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases
Luigi Cerbone, Benedetta del Rio, Sara Delfanti, Francesco Boccuzzi et al.
2025-12-31 · DOI: 10.1080/17581966.2024.2424133Oncogenic ALK fusion in rare subtype of small intestine metastasis from occult lung cancer
Tianhua Liu, Yizhuo Chen, Ziqing Xu, Ming Dong et al.
2025-12-31 · DOI: 10.1080/17581966.2024.2364582Cost of lung cancer diagnosis: cost differences between national health system and private sector
Paul Zarogoulidis, Vasilis Papadopoulos, Eleni-Isidora Perdikouri, Anastasios Vagionas et al.
2025-12-31 · DOI: 10.1080/17581966.2024.2370227Moving towards single fraction peripheral lung stereotactic body radiation therapy: patient care during and after the global COVID-19 pandemic
Salem Alfaifi, Vibhay Pareek, Julian Kim, Shrinivas Rathod et al.
2025-12-31 · DOI: 10.1080/17581966.2024.2367369Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis
Jon Lykkegaard Andersen, Jakob Sidenius Johansen, Edyta Maria Urbanska, Peter Meldgaard et al.
2024-02-28 · DOI: 10.2217/lmt-2023-0013Reviews
Community Reviews
Version History
October 4, 2026 at 9:20 pm
October 2, 2026